U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934642) titled 'Effect of Tirzepatide on Markers of MASLD in Patients With Obesity' on April 11.
Brief Summary: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD.
Participants will be asked to:
* Take tirzepatide for 12 months.
* Come ...